Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 2018, Article ID 1015239, 12 pages
https://doi.org/10.1155/2018/1015239
Review Article

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review

1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2Saw Swee Hock School of Public Health, National University of Singapore, Singapore
3Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Correspondence should be addressed to Jinyu Liu; moc.361@uynalyrrehc

Received 30 August 2018; Accepted 18 October 2018; Published 18 November 2018

Academic Editor: Sébastien Bonnet

Copyright © 2018 Ruxu You et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Tsai, Y. K. Sung, and V. de Jesus Perez, “Recent advances in the management of pulmonary arterial hypertension,” F1000Research, vol. 5, p. 2755, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. M. R. Wilkins, “Pulmonary hypertension: the science behind the disease spectrum,” European Respiratory Review, vol. 21, no. 123, pp. 19–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. E. M. Lau, E. Giannoulatou, D. S. Celermajer, and M. Humbert, “Epidemiology and treatment of pulmonary arterial hypertension,” Nature Reviews Cardiology, vol. 14, no. 10, pp. 603–614, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Galiè, M. M. Hoeper, M. Humbert et al., “Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT),” European Heart Journal, vol. 30, pp. 2493–537, 2009. View at Google Scholar
  5. G. E. D'Alonzo, R. J. Barst, S. M. Ayres et al., “Survival in patients with primary pulmonary hypertension: results from a national prospective registry,” Annals of Internal Medicine, vol. 115, no. 5, pp. 343–349, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. R. L. Benza, M. Gomberg-Maitland, D. P Miller et al., “The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension,” Chest, vol. 141, no. 2, pp. 354–362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Monaco and C. D. Davila, “Safety, efficacy, and clinical utility of in the treatment of pulmonary arterial hypertension,” Drug Design, Development and Therapy, vol. 10, pp. 1675–1682, 2016. View at Google Scholar
  8. L. Guillevin, I. Armstrong, R Aldrighetti et al., “Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives,” European Respiratory Review, vol. 22, no. 130, pp. 535–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Hutton, G. Salanti, D. M. Caldwell et al., “The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations,” Annals of Internal Medicine, vol. 162, no. 11, pp. 777–784, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. H. H. Hamberg-van Reenen, K. I. Proper, and M. van den Berg, “mental health interventions: a systematic review of economic evaluations,” Occupational and Environmental Medicine, vol. 69, no. 11, pp. 837–845, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. “CCEMG–EPPI-Centre Cost Converter, v. 1.5,” December 2016, http://eppi.ioe.ac.uk/costconversion/.
  12. K. B. Highland, C. Strange, J. Mazur, and K. N. Simpson, “Treatment of pulmonary arterial hypertension: a preliminary decision analysis,” Chest, vol. 124, no. 6, pp. 2087–2092, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. C. Garin, L. Clark, E. C. Chumney, K. N. Simpson, and K. B. Highland, “Cost-utility of treatments for pulmonary arterial hypertension,” Clinical Drug Investigation, vol. 29, no. 10, pp. 635–646, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Coyle, D. Coyle, J. Blouin et al., “Cost effectiveness of first-line oral therapies for pulmonary arterial hypertension: a modelling study,” Pharmacoeconomics, vol. 34, no. 5, pp. 509–520, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Dranitsaris and S. Mehta, “Oral therapies for the treatment of pulmonary arterial hypertension,” Applied Health Economics and Health Policy, vol. 7, no. 1, pp. 43–59, 2009. View at Publisher · View at Google Scholar
  16. J. H. Wlodarczyk, L. G. Cleland, A. M. Keogh et al., “Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia,” Pharmacoeconomics, vol. 24, no. 9, pp. 903–915, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. D. Stevenson, F. C. Macdonald, J. Langley, E. Hunsche, and R. Akehurst, “The cost-effectiveness of in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III,” Value in Health, vol. 12, no. 8, pp. 1100–1105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. S. Fan and W. J. H, “The cost-utility of bosentan in the treatment of pulmonary arterial hypertension patients,” Drug Evaluation, vol. 13, no. 8, pp. 13–19, 2016. View at Google Scholar
  19. M. Barbieri, W. Zamboni, L. Pippo, P. Madaan, and C. Campana, “Ambrisentan for the treatment of pulmonary arterial hypertension: a budget impact analysis in the Italian context,” Expert Opinion on Orphan Drugs, vol. 2, no. 10, pp. 989–997, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Marra, N. Benjamin, C Eichstaedt et al., “Gender-related differences in pulmonary arterial hypertension targeted drugs administration,” Pharmacological Research, vol. 114, pp. 103–109, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. R. L. Rhee, N. B. Gabler, S. Sangani, A. Praestgaard, P. A. Merkel, and S. M. Kawut, “Comparison of treatment response in idiopathic and connective tissue disease–associated pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 9, pp. 1111–1117, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Sculpher, F. S. Pang, A. Manca et al., “Generalisability in economic evaluation studies in healthcare: a review and case studies,” Health Technol Assess, vol. 8, no. 49, pp. 1–192, 2004. View at Publisher · View at Google Scholar · View at Scopus